20.40USD-4.49%Mkt Cap: 2.62B USDP/E: —Last update: 2026-06-01
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap2.62B USD
Enterprise Value2.27B USD
Revenue (TTM)8.40M USD
Gross Profit8.40M USD
Net Income (TTM)-243.32M USD
Revenue/Share0.0820 USD
Last Price20.40 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees225
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.31
PEG—
EV/EBITDA-5.21
EV/Revenue269.76
P/S327.76
P/B4.85
EPS (TTM)-1.78
EPS (Forward)-2.95
52W Range
2.76063% of range30.60
52W High30.60 USD
52W Low2.760 USD
Profitability
Gross Margin100.00%
Oper. Margin-5652.44%
EBITDA Margin0.00%
Profit Margin-1011.75%
ROE-80.76%
ROA-59.07%
Growth
Revenue Growth-90.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-369.52M USD
CapEx (TTM)653.00K USD
FCF Margin-2460.78%
FCF Yield-7.88%
Net Debt-487.28M USD
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity0.12
Current Ratio7.51
Quick Ratio7.41
Book Value/Sh4.457 USD
Cash/Share4.102 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)40.10 USD
Target Range25.00 USD – 55.00 USD
# Analysts10
Ownership
Shares Out.123.43M
Float85.87M
Insiders0.64%
Institutions99.68%
Short Interest
Short Ratio10.8d
Short % Float15.85%
Short % Out.8.91%
Shares Short11.36M
Short (prev mo.)12.21M
Technical
SMA 5023.70 (-13.9%)
SMA 20015.36 (+32.8%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)915.73K
Avg Vol (10d)819.62K
Technical Indicators
RSI (14)38.8
MACD-0.7938
MACD Signal-0.6077
MACD Hist.-0.1861
BB Upper26.44 USD
BB Middle23.21 USD
BB Lower19.98 USD
BB Width27.87%
ATR (14)1.300 USD
Vol Ratio (20d)0.49x